The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Riluzole Zentiva riluzole | Zentiva k.s. | Amyotrophic Lateral Sclerosis | 🇪🇺 EU 2012-05-07 | Order → |
| Signifor pasireotide | Recordati Rare Diseases | Acromegaly; Pituitary ACTH Hypersecretion | 🇪🇺 EU 2012-04-24 | Order → |
| Capecitabine Accord capecitabine Generic | Accord Healthcare S.L.U. | Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2012-04-20 | Order → |
| Capecitabine Teva capecitabine Generic | Teva Pharma B.V. | Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2012-04-20 | Order → |
| Ecansya (previously Capecitabine Krka) capecitabine Generic | KRKA tovarna zdravil d.d. Novo mesto | Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2012-04-20 | Order → |
| Nimenrix meningococcal groups A, C, W-135 and Y conjugate vaccine | Pfizer Europe MA EEIG | Meningitis, Meningococcal | 🇪🇺 EU 2012-04-20 | Order → |
| Sancuso granisetron | Grünenthal GmbH | Vomiting; Cancer | 🇪🇺 EU 2012-04-20 | Order → |
| Zoledronic acid Actavis zoledronic acid Generic | Actavis Group PTC ehf | Fractures, Bone | 🇪🇺 EU 2012-04-20 | Order → |
| Bronchitol mannitol | Pharmaxis Europe Limited | Cystic Fibrosis | 🇪🇺 EU 2012-04-13 | Order → |
| Sabervel irbesartan Generic | Pharmathen S.A. | Hypertension | 🇪🇺 EU 2012-04-13 | Order → |
| Pioglitazone Teva pioglitazone Generic | Teva B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-26 | Order → |
| Pioglitazone Teva Pharma pioglitazone Generic | Teva Pharma B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-26 | Order → |
| Paglitaz pioglitazone Generic | KRKA tovarna zdravil d.d. Novo mesto | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-21 | Order → |
| Pioglitazone Accord pioglitazone Generic | Accord Healthcare S.L.U. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-21 | Order → |
| Pioglitazone Krka pioglitazone Generic | KRKA tovarna zdravil d.d. Novo mesto | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-21 | Order → |
| Glidipion (previously Pioglitazone Actavis Group) pioglitazone Generic | Actavis Group PTC ehf | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-15 | Order → |
| Pioglitazone Actavis pioglitazone Generic | Actavis Group PTC ehf | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-15 | Order → |
| Sepioglin pioglitazone Generic | Vaia S.A. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-03-09 | Order → |
| Xaluprine (previously Mercaptopurine Nova Laboratories) mercaptopurine | Lipomed GmbH | Leukemia, Lymphoid | 🇪🇺 EU 2012-03-09 | Order → |
| Esmya ulipristal | Gedeon Richter Ltd | Leiomyoma | 🇪🇺 EU 2012-02-22 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.